Genetic counselors (GCs) have reported an increase in discussion of insurance-related, or Bgenesurance,^topics during genetic counseling sessions. Despite increasing frequency, there have been no studies examining patient expectations of GCs in these discussions. This study aimed to explore patient expectations of GCs in these discussions, as well as examine factors that may impact expectations. A 38-item survey was administered prior to patients receiving prenatal or cancer genetic counseling at 11 clinic sites across UTHealth, Baylor College of Medicine, and Sanford Health, with 360 responses analyzed. Key variables were analyzed using descriptive statistics, chi-square analysis, and multivariate logistic regression to assess associations between factors and control for potential confounders. Over 75% of patients expected GCs to discuss genesurance topics during a genetic counseling session. The majority of patients (78%) expected GCs to provide an estimated out-of-pocket cost, know if a test is a covered benefit (77%), and provide referral information for further questions (76%). Two additional expectations, considered to be unrealistic in most clinical settings, included expecting GCs to know the patient's specific insurance plan and coverage information (57%) and provide an exact out-of-pocket cost (41%). Ethnicity was the only significant predictor of response for these two expectations, as African Americans and Hispanics were more likely than Caucasians to have these beliefs. While the patient participants felt that GCs were primarily responsible for initiating these conversations, they also reported a personal sense of responsibility for raising questions. This study demonstrates that patients may expect GCs to address genesurance topics in a genetic counseling session, with specific expectations about the cost and coverage of genetic tests. Further studies will establish the most effective way to communicate this information to patients and examine whether and where within the scope of GC practice, genesurance discussions fall.
Discussions about potential costs of diagnostic tests, prescriptions, and treatment options are often uncomfortable and awkward for healthcare providers to have with patients (Alexander et al. 2003) . The absence of these conversations during the decision-making process has been attributed to insufficient provider training and time limitations (Alexander et al. 2003; Riggs and Ubel 2014) and may have negative effects like Bfinancial toxicity,^or increased financial burden for patients, resulting in consequences to their health and wellbeing (Ubel et al. 2013; Zafar et al. 2013) . With the acknowledgment of the importance of these conversations and patients' desires to have them, it is critical that healthcare providers begin to understand patient expectations in discussing healthcare costs (Alexander et al. 2003; Patel and Wheeler 2014; Ubel et al. 2013) .
The rapidly expanding field of genetics and the advent of next-generation sequencing technologies have resulted in an increase in both genetic tests and genetic testing laboratories Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10897-018-0211-2) contains supplementary material, which is available to authorized users.
(BGeneTests,^https://www.genetests.org/; BGenetic Testing Registry,^https://www.ncbi.nlm.nih.gov/gtr/). However, uptake of genetic testing is often limited due to issues with obtaining insurance coverage (Capasso 2014; Spoonamore and Johnson 2016; Uhlmann et al. 2017) . Discussing and obtaining insurance coverage for genetic testing is often a multistep, time-intensive process, which frequently requires both genetic counselor (GC) and physician participation, posing challenges for both providers and patients (Brown 2016; Uhlmann et al. 2017) .
With increasing frequency, GCs across a wide variety of specialties find themselves discussing insurance coverage of genetic testing during genetic counseling sessions (Brown 2016) . These discussions have been termed Bgenesurance counseling,^defined as the portion of a genetic counseling session that is devoted to the topic of costs and insurance coverage of genetic testing. One estimate is that, on average, 8 min of a genetic counseling session is dedicated to discussing genesurance topics (Brown 2016) . Additionally, GCs report on average spending an additional 4.5 h per week outside of a genetic counseling session dealing with genesurance-related tasks like writing letters of medical necessity, submitting pre-authorizations, and following up with patients about insurance-related matters (Brown 2016) . According to the 2016 Professional Status Survey by the National Society of Genetic Counselors, prenatal and cancer counselors see 12-16 new patients on average each week (NSGC 2016) . Extrapolating these estimates, GCs could be spending up to 6.5 h, or approximately 17%, of a typical 40-h work week addressing genesurance topics both during and after a genetic counseling session.
Given the growing amount of time devoted to these topics by GCs, understanding patient expectations is integral in devising methods to meet these expectations while maximizing GC skills and efficiency. This study aims to explore patient expectations of GCs in genesurance discussions during a genetic counseling session, as well as factors that may impact those expectations. By examining this relationship, we hope to further define the role of a genetic counselor in these genesurance discussions, assess the need for further insurance-related training, and highlight areas for future research. From August 22, 2016 , through January 27, 2017 
Methods

Participants
Instrumentation and Procedures
Eligible participants were provided a copy of the survey along with additional clinic paperwork by front desk staff when they checked in for their genetic counseling appointment. Patients willing to participate completed the survey in the waiting room prior to receiving genetic counseling. Deidentified responses from the survey were collected and recorded in a secure electronic database. The survey, totaling 38 questions, consisted of four sections: demographics, a validated Health Insurance Literacy Measurement tool (HILM) (Paez et al. 2014) , assessment of patient expectations of GCs in genesurance discussion, and a free response opportunity.
The survey was developed by investigators based on anecdotal clinical experience and published literature (Brown 2016) . Questions were designed to specifically assess (1) patient expectations of GCs in terms of the content and depth of genesurance discussions, (2) how long and when these conversations should take place during a genetic counseling session, (3) patient expectations of genesurance discussions in other healthcare settings (i.e., outside of genetic counseling), and (4) who is responsible for initiating genesurance discussions. The survey was piloted to both individuals with and without genetic counseling experience. On average, it took these individuals 15-20 min to complete the survey-however, average completion time was not assessed from actual participants in the study. For the purpose of this study, we define the term Bgenesurance counseling^as the portion of the genetic counseling session, whether intentional or unintentional, that is devoted to the topic of costs and third party coverage of genetic testing.
Data Analysis
Data were analyzed using data analysis and statistical software STATA v.13 (College Station, TX). Descriptive statistics were calculated for all variables using means and standard deviations for continuous variables and frequency and percent for categorical responses. Key variables were compared using chi-square analysis, and multivariate logistic regression was used to assess associations between factors, while controlling for potential confounders. Multivariate logistic regression assessed the following variables: income, ethnicity, type of insurance, and country of origin. Health insurance literacy was assessed using a validated tool (Paez et al. 2014 ) and was not found to be statistically significant in predicting patient expectations and was, therefore, not included in multivariate models. Statistical significance was assumed at a type I error rate of 5%. Free responses were analyzed using grounded theory in which emerging themes were identified by principal investigators during an initial review of responses. Final coding was assigned by a single principal investigator for consistency.
Results
A total of 365 patients took part in this survey across all participating institutions (Fig. 1) . Responses from participants who only completed the demographic section were eliminated, leaving 358 responses for analysis. Not all respondents completed the survey in its entirety, resulting in lower response rates for some questions.
The mean age of the sample was 36 years. The majority (59.8%) of participants were receiving prenatal genetic counseling (n = 214), while 28.5% were receiving cancer genetic counseling (n = 102), and 11.7% of participants were unsure about which type of genetic counseling they would be receiving (n = 42). At least four clinic sites saw both prenatal and cancer patients, which could have contributed to confusion about the type of counseling participants would be receiving. Additionally, two clinic sites saw preconception patients, which was not an explicit option on the survey. As outlined in Table 1 , most participants self-identified as Caucasian (58.3%) or Hispanic (19.7%) and reported having private insurance (73.5%). Prefer not to answer 39 11.1
Patient Expectations of Genetic Counselors
Overall, 75.1% of respondents indicated that they expect their genetic counselor to discuss genesurance-related topics during a genetic counseling session. Within those discussions, the majority of individuals expect their genetic counselor to provide an estimated out-of-pocket cost (n = 278), know if a test or procedure is a covered benefit (n = 276), and provide contact or referral information if they have additional genesurance-related questions (n = 272). Other expectations included GCs providing information regarding cost and coverage specific to each individual's insurance plan (n = 205) and providing an exact OOP cost for genetic tests (n = 145) (Fig. 2) . Various factors were significantly associated with patient expectations of GCs. However, many of the factors (e.g., type of insurance and how respondents obtain insurance) are associated with each other. Therefore, secondary analyses using multivariate logistic regression models were performed to assess for effect modification or confounding. These models demonstrated that ethnicity was the only significant independent predictor of two patient expectations: (1) GC providing individualized information based on a patient's insurance plan and coverage and (2) GC providing an exact out-of-pocket cost.
Hispanics were 2.59 times more likely to expect personalized insurance information from their genetic counselor than Caucasians (p = 0.045), while African Americans were 4.04 times more likely to expect this specific information from their counselors than Caucasians (p = 0.008). In regard to expecting an exact out-of-pocket cost, Hispanics were 2.31 times more likely to expect this than Caucasians (p = 0.016), while African Americans were 2.36 times more likely to expect this than Caucasians (p = 0.035). Other expectations were not influenced by a single predominant factor.
The type of genetic counseling patients were receiving also impacted their expectation of the GC providing an exact out-of-pocket cost. Individuals receiving prenatal counseling were 1.75 times more likely to expect an exact out-of-pocket cost than individuals receiving cancer counseling (p = 0.031). There were no other statistically significant differences observed between individuals receiving different types of genetic counseling.
Of note, a validated HILM was used to assess and compare health insurance literacy (HIL) among participants (Paez et al. 2014) . Overall health insurance literacy did not impact patient expectations of GCs regarding genesurance discussions.
Impact, Length, and Timing
Over 67% of respondents believed that genesurance discussions can alter their decision-making process and ultimately impact whether or not they pursue genetic testing. Almost 79% preferred genesurance discussions to take place before they make a decision about pursuing genetic testing, another 9% preferred these discussions to take place after they have made a decision regarding testing, and another 9% of patients only wanted to discuss these topics when they brought them up themselves. About 3% did not want their counselor to address these topics at all. In terms of the length of genesurance conversations, 30% of participants wanted to spend less than 5 min discussing these topics, 38% wanted to spend 5-10 min, 26% wanted to discuss these topics until they had no more questions, 4% did not want to spend time discussing these topics at all, and 2% wanted to spend more than 10 min on these topics.
Responsible Parties
Over 90% of patients reported feeling a personal responsibility to ask genesurance-related questions in a genetic counseling session. When given the option to select all individuals they felt were responsible for genesurance discussions from a list that included GCs, physicians, representatives from the insurance company, diagnostic laboratory, provider's billing office, administrative support personnel, and themselves, respondents chose an average of two individuals (Fig. 3) . Of the 800 selections, the most frequent response was genetic counselor (n = 185) followed by personal responsibility (n = 142). The least frequent responses were administrative personnel (n = 86) and diagnostic laboratory (n = 28).
Patient Expectations of Primary Care Providers
Participants were asked to evaluate their interactions with primary care providers and their expectations of insurancerelated discussions during these visits. When reflecting on these interactions, 37% (n = 125) of participants expected insurance coverage to be discussed at every visit, 26% (n = 89) expected these conversations only under certain circumstances such as blood work, imaging studies, or procedures, while 25% (n = 87) of patients did not expect these conversations to take place at all with primary care providers. Of note, 10% (n = 36) of respondents reported that they had not considered insurance coverage discussions in their conversations with primary care providers before taking this survey.
Free Response
Of the 359 surveys analyzed, 166 participants responded to the free response question which asked how healthcare providers, including GCs, could best help patients understand their health insurance information. When reviewing these results, eight main themes emerged among the responses including coverage and cost of tests or procedures (n = 117), desire for their provider to have knowledge of insurance-related issues (n = 90), desire to have a conversation about these issues (n = 62), responsible parties (n = 37), having tangible resources for reference outside of the appointment (n = 19), lack of familiarity with the genetic counseling and testing process (n = 15), timing of the conversation (n = 11), and the impact on decision-making (n = 5). The free responses covered a broad range of expectations, suggestions, and feelings (Table 2) .
Discussion
This study explored patient expectations of GCs in genesurance discussions during a genetic counseling session. The results of this study (1) demonstrate patients' desire to have these conversations; (2) delineate expectations regarding the content, timing, and length of genesurance conversations; and (3) indicate whom patients feel are responsible for having these discussions. These findings are consistent with reports from GCs delineating frequency, timing, and impact of these discussions (Brown 2016) , while contributing patient perspectives to the growing body of literature on this topic.
Addressing Patient Expectations
The majority of patients (75.1%) expected their GC to address genesurance-related topics during their genetic counseling session. Certain expectations like providing an estimated out-of-pocket cost, knowing if a test will likely be a covered benefit, and referring patients to other qualified individuals are reasonable to address during a genetic counseling session.
In both prenatal and cancer genetics settings, commonly offered tests such as cell-free circulating tumor DNA tests, cell-free circulating fetal DNA tests, or pan-cancer germline panels may have readily accessible list prices through diagnostic laboratory websites or company representatives. In addition, some diagnostic laboratories have billing support or online tools aimed at providing estimated out-of-pocket costs based on the patient's insurance information. Others have billing processes in place that allow them to contact the patient if their out-of-pocket cost is over a certain amount, giving the patient the opportunity to proceed, decline, or choose a selfpay option. By familiarizing themselves with these billing policies, tools, and list prices, GCs may feel better equipped to provide this information as a point of reference to patients, addressing their expectations regarding out-of-pocket cost estimates.
In terms of covered benefits, many insurance companies use national guidelines from professional societies Who is responsible for discussing insurance topics? , to help inform testing criteria and determine coverage. These guidelines and clinical judgment can both be used to provide guidance as to whether a genetic test would likely be a covered benefit for an individual patient. In some situations, GCs may not be able to fully answer patient questions regarding insurance-related topics. In this case, providing contact information for the diagnostic laboratory or for a billing representative or staff member who can further address these questions may be an option. A substantial number of respondents had expectations to discuss information not traditionally provided during a GC session, including GCs having personal knowledge of their specific insurance plan and coverage (57.3%) and being provided an exact out-of-pocket cost (40.5%). Given the number of unique insurance companies and plans, GCs would never be able to have personal and specific knowledge of each patient's plan. Furthermore, providing an exact out-of-pocket cost is not feasible for any medical provider, given the nuances within each individual's plan (i.e., deductibles, co-pays, etc.) as well as the specifics regarding contracts between insurance companies and diagnostic testing laboratories.
Interestingly, ethnicity was the only significant demographic predictor of these two expectations. Compared to Caucasians, both Hispanics and African Americans were more likely to expect these two actions from their GCs. It is well documented that individuals in these ethnic groups are less likely to utilize healthcare services (Blumberg et al. 2014; Long and Goin 2014; Morgan et al. 2008 ). This limited utilization may be contributing to misconceptions and unrealistic expectations, due to an overall unfamiliarity with healthcare provider interactions and should be considered when developing strategies to address these misconceptions.
The proportion of patients who expect this depth of knowledge is concerning and may indicate a fundamental misunderstanding of health insurance, specialized testing, and the third party payor system. Many free responses also echoed a feeling of uncertainty or lack of familiarity about the genetic testing process. This finding highlights an opportunity for the development of patient-friendly educational materials, such as brochures and videos that explain the genetic testing process in the context of insurance policies and procedures. National organizations like NSGC could capitalize on this education opportunity. The development and dissemination of patient education materials may help alleviate the burden on GCs to explain the process and allow them to focus on other patient concerns.
Genesurance Discussions in Practice
Considering the fact that over 67% of respondents felt that genesurance discussions might alter their decision to pursue genetic testing, it is not surprising that a large majority of patients wish to discuss these issues prior to making a decision. Based on the survey responses, the majority of patients would like to spend up to 10 min discussing genesurance topics during a session. This finding is consistent with the study of Brown (2016) in which GCs reported spending 8 min on average exploring genesurance topics in a session. Coverage and cost concerns (n = 117) BBe familiar with cost/estimate or give information about where to easily get the info elsewhere.P rovider knowledge (n = 90) BBy knowing which test are broadly covered by most (major, private) insurance companies, then by advising the patient of their expected OOP expenses.D esire to have a conversation (n = 62) BThere needs to be a discussion… whether through the counselor, the doctor, or a billing person.R esponsible parties (n = 37) Personal responsibility BMy [provider] doesn't know the plan coverage I have and it's my responsibility to find out by calling the insurance company to find out if a procedure or testing is covered.P rovider responsibility BI believe any [provider] should advise patients to contact their insurance provider to discuss coverage, as some tests may or may not be covered.Ŝ Others mentioned providing patients with CPT codes so that they could contact their insurance company:
Provide complete diagnosis testing codes [so] that I may contact my insurance to confirm prices for testing Prompt [patients] to contact insurance company to check the genetic tests recommended. Perhaps give a checklist of things for individuals to ask of their insurance.
Who Is Responsible for Genesurance Discussions?
Respondents indicated that the two major parties responsible for genesurance discussions are GCs and the patients themselves. This indicates a willingness on behalf of the patient to be an active participant and alludes to a shared responsibility between providers and patients in these discussions.
Interestingly, patients felt diagnostic laboratories were least responsible for addressing genesurance topics, when they are likely the best sources of information for patients regarding their individual coverage and cost of genetic tests. This highlights the potential for diagnostic laboratories to address this misconception and step into the gap and aid in patient education and overall understanding of the genetic testing process.
To do this, diagnostic laboratories must address both provider and patient needs in terms of understanding billing policies and procedures. To address ordering provider needs, diagnostic laboratories should feature clearly delineated and readily accessible billing policies on their websites and test requisition forms. Accessibility and transparency in list prices, contracted insurance companies, and billing policies could alleviate GC time spent researching these topics outside of a genetic counseling session.
Laboratories may further distinguish themselves from competitors by offering robust customer service personnel dedicated to financial and billing topics available to providers and their patients. In this way, GCs can provide their patients referral information to the best sources of information regarding the billing and coverage of genetic tests, and laboratories can help reduce the amount of time spent discussing these topics in a clinical setting.
Primary Care Provider Differences
Although over 75% of patients expected insurance-related topics to be addressed in a genetic counseling session, only 37% of patients expected these topics to be addressed at every visit in a primary care setting. This could demonstrate that patients have higher expectations of more specialized providers. Compared to other medical tests or procedures patients routinely encounter, Bgenetic testing^may have a Bnonroutine^connotation, which can heighten patient anxiety, and perhaps their expectations from providers. Alternatively, in many settings, genetic testing is presented as an optional, patient-centered choice, which may contrast with other areas of medicine where medical decisions are presented in a more directive manner. Future investigation comparing patient expectations of specialty providers versus expectations of GCs or other genetics providers may elucidate whether the differences observed in this study are specific to genetic counseling or to all specialized medicine.
Genesurance Discussions and GC Efficiency
Given the high and difficult-to-meet demand for GCs in both clinical and nonclinical positions, it is important that GCs maximize the use of their specialized skill sets to perform tasks only they can do, while delegating other tasks (Pan et al. 2016) . It remains to be determined if GCs are the most appropriate, qualified, and costeffective individuals to have genesurance conversations, especially in light of current workforce issues, and further research is warranted. Utilizing appropriate staff members, collaborating with diagnostic laboratories' customer service teams, and evaluating and optimizing current clinic workflow may provide alternative solutions to address these patient expectations while maximizing GC efficiency (Pirzadeh-Miller et al. 2016; Uhlmann et al. 2017) .
Future Research
This study highlights opportunities for further research on the topic of insurance-related discussions in a genetic counseling session. Considering the frequency of these discussions and patients' expectations to have them, future research is needed to investigate current training practices of genetic counseling training programs in insurance-related topics. Identifying the source(s) of patients' expectations regarding the discussion of insurance-related topics is also needed. Additionally, research addressing GC efficiency and genesurance-related tasks, as well as whether and where this should fall within the GC scope of practice, is warranted. Finally, investigation into the impact of genesurance discussions on GC burnout or disinterest in clinical positions may become increasingly relevant, should the frequency of these conversations increase.
Study Limitations
Although this study is the first to explore patient expectations of GCs in genesurance discussions, there are limitations that should be taken into account when interpreting the study findings. Individuals who participated in the study may differ in important ways from nonparticipants. For instance, participants likely had stronger opinions or expectations in genesurance discussions, while individuals who declined to participate may have represented individuals with lower health insurance literacy or individuals who had neutral or ambivalent opinions about the discussion of genesurance topics. These differences may have led to a self-selection bias. Additionally, the survey was only administered to individuals who presented for genetic counseling, which may have excluded individuals who declined a visit due to insurance concerns. The survey was carefully developed to evaluate the aims of this study; however, with the exception of a validated health insurance literacy tool, the study materials were not validated. The study was made up of patients seen for a mixture of indications. It is likely that motivations and perceived barriers to genetic testing may be different among individuals receiving prenatal or cancer genetic counseling and this may have influenced individuals' responses but was not assessed for in this study.
Conclusions
There is no denying that navigating insurance-related discussions in a healthcare setting can be complex and uncomfortable. However, GCs have a unique skill set designed to educate patients about complex issues, tailor information to individual needs, and promote informed decision-making. While these skills can help facilitate genesurance discussions in a genetic counseling session, it remains unclear whether these discussions should fall within the scope of practice of genetic counselors and what the best strategies are to approach this complex topic in order to maximize GC competency-based skills.
A variety of strategies were suggested for individual GCs to address genesurance-related topics within their practice. While these strategies can be currently implemented, careful evaluation of clinic workflow and utilization of other individuals may alleviate the burden felt by GCs to address genesurance issues. NSGC can further aid these efforts by creating patient-friendly educational materials to address basic concepts of genetic testing in the context of insurance coverage and billing. Additionally, diagnostic laboratories can contribute to patient education by developing billing tools to promote patient self-advocacy. Furthermore, diagnostic laboratories can promote billing transparency and accessibility to billing staff in order to simplify an overwhelmingly complex topic.
In the age of personalized medicine, it is clear that patients expect and desire to have all aspects of their healthcare customized, including conversations about insurance coverage. While genesurance discussions may pose unique challenges in a genetic counseling session, they have become an integral part of our practice, indicating the need for further assessment, training, and research in these topics.
